Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlobalData Regulatory News (DATA)

Share Price Information for GlobalData (DATA)

Share Price is delayed by 15 minutes
Get Live Data
92.50    -0.10 (-0.11%)
Bid:
92.90
Ask:
94.00
Spread: 1.10 (1.184%)
Market Cap: £642.50m
DATA Live PriceLast checked at - London Stock Exchange

Intraday GlobalData Share Chart

Board changes

19 Jan 2026 07:00

RNS Number : 3175P
GlobalData PLC
19 January 2026
 

19 January 2026

 

 

GlobalData Plc (GlobalData; the Company)Board changes

 

GlobalData Plc, a leading data, insights, and technology company, is pleased to announce the appointment of Rachel Higham as an independent non-executive director with effect from 20 January 2026.

Rachel brings to the board more than 30 years of experience in the information technology sector, having held senior roles at Marks & Spencer, WPP, BT and Vodafone.

In accordance with Schedule 2(g) of the AIM Rules for Companies, Rachel Higham is 51 years old. In the last 5 years she has been, and still is, a director at RHigham Consulting Limited and director and trustee at Macmillan Cancer Support. There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.

This appointment is part of wider changes being announced with respect to the board's independent non-executive directorships. Both Annette Barnes and Andrew Day will not offer themselves for re-election as a director at the 2026 Annual General Meeting given they would, at that time, have served on the board for more than nine years from the date of their first appointment. Annette and Andrew will resign from office prior to the Company announcing its 2025 full year results on 2 March 2026.

Rachel is being appointed to succeed Andrew Day and a further appointment to succeed Annette Barnes is expected to be announced shortly. 

 

Mike Danson, Chief Executive Officer of GlobalData, commented:

"On behalf of the board, I would like to thank Annette and Andrew for their exceptional support and guidance over the last nine years during which time GlobalData has evolved into a globally recognised market leader. We wish them all the best for the future."

"I am also delighted to welcome Rachel to the GlobalData team. Rachel will bring a wealth of knowledge and expertise to our board both from her experiences within the technology sector, but also from her focus and passion for data and innovation.''

 

-ENDS-

 

 

ENQUIRIES

GlobalData Plc

0207 936 6400

Mike Danson, Chief Executive Officer

Graham Lilley, Chief Financial Officer

J.P. Morgan Cazenove (Nomad, Joint Broker)

0203 493 8000

Bill Hutchings

Mose Adigun

Panmure Liberum (Joint Broker)

0203 100 2000

Rupert Dearden

James Sinclair-Ford

 

Investec Bank plc (Joint Broker)

Henry Reast

0207 597 5970

Virginia Bull

FTI Consulting (Financial PR)

0203 727 1000

Edward Bridges

globaldata@fticonsulting.com

Dwight Burden

Emma Hall

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGPUQWGUPQPUQ
Date   Source Headline
12th Mar 20241:35 pmRNSDirector/PDMR Shareholding
12th Mar 20241:30 pmRNSHolding(s) in Company
4th Mar 20247:00 amRNSFull Year Results
1st Feb 20243:49 pmRNSHolding(s) in Company
1st Feb 20247:00 amRNSDirector/PDMR Shareholding
1st Feb 20247:00 amRNSDirector/PDMR Shareholding
24th Jan 20247:00 amRNSInvestor and Analyst Seminar
11th Jan 20247:00 amRNSTrading Update & Announcement of Investor Seminar
29th Dec 20237:00 amRNSDirector/PDMR Shareholding
21st Dec 20237:00 amRNSInvestment in Healthcare Division by Inflexion
16th Nov 20237:00 amRNSDirector/PDMR Shareholding
13th Sep 202310:48 amRNSDirector/PDMR Shareholding
13th Sep 202310:41 amRNSDirector/PDMR Shareholding
8th Aug 20235:41 pmRNSDirector/PDMR Shareholding
8th Aug 20235:35 pmRNSDirector/PDMR Shareholding
31st Jul 20237:00 amRNSHalf Year Results
25th Jul 20232:58 pmRNSResults of General Meeting
7th Jul 20237:00 amRNSNotice of General Meeting
30th Jun 202310:00 amRNSDirector/PDMR Shareholding
25th Apr 20233:34 pmRNSResult of AGM
25th Apr 20237:00 amRNSAGM Trading Update and Notice of AI Seminar
29th Mar 20237:00 amRNSNotice of Annual General Meeting 2023
17th Mar 20236:02 pmRNSAnnual Report for year ended 31 December 2022
27th Feb 20237:00 amRNSFull Year Results
27th Jan 20234:31 pmRNSDirector/PDMR Shareholding
27th Jan 20234:26 pmRNSHolding(s) in Company
27th Jan 20239:28 amRNSDirector/PDMR Shareholding
24th Jan 20237:00 amRNSCapital Markets Day
18th Jan 202311:47 amRNSPDMR Dealing
10th Jan 20237:00 amRNSFull year trading update
10th Nov 20224:41 pmRNSSecond Price Monitoring Extn
10th Nov 20224:36 pmRNSPrice Monitoring Extension
17th Oct 20229:44 amRNSHoling(s) in Company
17th Oct 20228:44 amRNSHolding(s) in Company
14th Oct 20227:00 amRNSDirector/PDMR Shareholding
5th Sep 202210:59 amRNSHolding(s) in Company
2nd Sep 20227:00 amRNSCompletion of TS Lombard Acquisition
15th Aug 20227:00 amRNSDirector/PDMR Shareholding
15th Aug 20227:00 amRNS£82m Share Scheme Vests for 146 Employees
10th Aug 20227:00 amRNS£410million Debt Financing Facility
1st Aug 20227:00 amRNSHalf Year Results
20th Jul 20227:00 amRNSAppointment of Joint Broker
15th Jul 20227:00 amRNSNotice of Interim Results
28th Jun 202212:45 pmRNSAnnual Report FY2021
26th Apr 202212:32 pmRNSResults of AGM
4th Apr 20221:14 pmRNSNotice of AGM
28th Feb 20227:00 amRNSFinal Year Results
24th Feb 20227:00 amRNSHolding(s) in Company
14th Jan 20224:43 pmRNSPDMR Notification
10th Jan 20227:00 amRNSUpdate on FY21 performance and Capital Markets Day

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.